Upload
guest25c0ae
View
385
Download
0
Embed Size (px)
Citation preview
Columbia Life Systems, Inc.
SmartBlender™
1
Columbia Life Systems, Inc.Redefining the standards of respiratory care
2
Making babies healthier…
one breath at a time.
3
Dr. Jay Greenspan, Chief of Neonatology
Thomas Jefferson University Hospital
Philadelphia, PA
June 2007
“We (currently) have 1950’s medicine in the 21st century”
“It’s a little embarrassing that we don’t have a mechanized way”
4
The SmartBlender™An adaptive controlled oxygen blender utilizing
novel, ‘smart’ technology
• Delivers continuous supplemental oxygen to newborn babies/patients in respiratory distress
Maintains baby’s blood-oxygen level, as assessed by a pulse oximeter, at a set range specified by a physician, continuously.
Components:Pulse OximeterOxygen BlenderComputer: Software/Algorithms
5
SmartBlender™ Technology: Adaptive, Dynamic, Continuous, Accurate
6
SmartBlender™ Value Proposition
The SB promotes automatic, adaptive and consistent maintenance of blood saturation which will reduce or eliminate development of acute and chronic health problems due to unregulated oxygen therapy.
• Pneumonia, bronchio-pulmonary displasia, retinopathy are just a few of the conditions that can result from inhalation of excessive oxygen amounts.
• Clinical study at Pennsylvania Hospital, Philadelphia, PA has indicated: the weaning of patients from oxygen sooner, which may reduce patient length of stay in NICU.
• Reduction in patient stay affects hospitals’ bottom line, therefore reducing costs, increasing profitability
• Neonatologists believe: SB promotes better lung health
7
CLS: The right combination
Management believes the four most important advantages
of the SmartBlender™:
Clinical and therapeutic effectiveness
Strong receptivity from physicians
Clear path to product reimbursement
Reduced cost of treatment
8
Columbia Life Systems, Inc.:
The journey: concept to clinical trial
9
The process1985 Concept
Phospho-Energetics
1987 SmartBlender™ patent
Otsuka Electronics
1992 Ventilator patent
1998 Varian
NC Biotechnology Dr. Robert Black
1999 Mallinckrodt/Tyco
Ohmeda/Hill-Rom
2000 Hill-Rom/Air-Shields
Tri-Virix International
2003 Draeger Medical
2007 Respironics
SmartBlender™ additional patents
2009 Clinical trial at Cooper University Hospital
and beyond!
10
Competitive position: Intellectual Property
First patent (#4,886,116) filed 1985
2nd and 3rd patents pending (38 claims)Solenoid system for oxygen controlDisplay and User InterfaceMethods (CPAP, long-term therapy, Heliox, sleep
apnea, weaning, newborn, adult)Alarm featuresApnea control
“Adaptive Controller for Automatic Ventilators” (patent #5,388,575) filed 1992 -SmartTap™
11
Market: competitive landscape
Fixed concentration oxygen blenders, adjusted manually, are the industry standard
Four companies control lion’s share of market
No adaptive smart technology blenders are available in the hospital space
Bottom line: No competition at this time globally
CLS: preparing for market entry
12
Pediatric and Adult SmartBlender™ Market Applications
13
Pediatric NICUSmartBlender™ Market
14
INFANT Potential: Primary NICU market niche
15
Adult ICU SmartBlender™ Market
16
ADULT Potential: Primary (US) ICU market niche
17
SmartBlender™ Market Applications ADDITIONAL AREAS
18
SB Market Revenue Projections:
Total Market US: $ 276MNICU & ICU
Additional market NICU WW: $ 63M9000 units @ 75% adoption
Additional Market Areas: ER, Post extubated, Transport, Recovery, TBD* COPD, Sickle Cell
Total Market Size: $339M ++
19
SmartTap™ Ventilator market“Adaptive Controller for Automatic Ventilators”
(patent #5,388,575) filed 1992
Integration of SB ‘smart’ technology into active, mechanical ventilation (i.e. for intubation)
Worldwide market size is double the combined infant NICU and adult ICU markets: 100,000 + units
Priced similarly to SmartBlender™ SmartTap™ Projected revenue: $700M
20
Moving forward to the
Marketplace
21
Pathways to the Marketplace
A. B. Clinical trial
concurrent with product re-design
Submission of 510(k)
FDA clearance
Sale of CLS
Clinical trial concurrent with product re-design
Submission of 510(k)
FDA clearance
Manufacturing of SB for sales to US luminary hospitals
Sale of CLS
Regulatory: 510(k) pathway process to FDA clearance
1. IRB: Investigational Review Board approval 1.9.09 Cooper University Hospital, Camden, NJ
Utilization of Predicate device code approved via 510(k): MITI OptiSat
2. Clinical Trial: comprised of 40-60 patients at CUH for 90 days, commencing March 2009
3. 510(k) Application: submission for FDA clearance utilizing trial data
4. FDA clearance time frame: within 60 days of application submission
23
SmartBlender™ Re-design Objectives
1.Replace computer board
2. Reduce weight and size by 50%
3. Improve industrial design: aesthetic andergonomic modifications
4.Reduce manufacturing cost from $1,800/unit to $860/unit
5.Submit enhanced design with trial data for FDA clearance
24
Health and Market Information
US infant mortality increasing: ranked 180/222 countries - 42nd in the world with 6.30 deaths/thousand*
World infant mortality: 49.4 deaths/thousand* 42.64 deaths/thousand according to CIA World Fact Book
Number of premature births continues to rise: IVF procedures and multiple births are on the rise
Number of NICU beds continues to grow
National healthcare initiative: lower cost of treatment and increase standard of care *according to United Nations
25
Market Receptivity: What are they saying?*
“concept is superb …great for RNs” “makes sense … would keep baby’s SATs in
medically desired range” “may improve outcomes … important to our practice
…purchase would be a high priority”
“we are not titrating O2 very well … could shorten hospital stay”
“we’re currently using 1950s medicine in the 21st century”
* excerpts from doctors and clinicians
26
Market Pricing: What would they pay?
Dr. L $7K
Dr. LB $6-7K
Dr. B No opinion
Dr. EB $7-8K
Dr. W $5-6K
MEAN: $7, 000
27
“This (SmartBlender) is a winner”
Augustine Legido MD, PhD, MBAChief of Neurology St. Christopher’s Hospital for ChildrenPhiladelphia, PA
28
Columbia Life Systems: down to
business
29
Who we areCorporate John Taube
President and Founder
Brad ColemanSoftware
Larry PopeEngineering
Lois Smart Regulatory
Linda D. RoccaMarketing
Medical Advisors
Vinod Bhutani, MD Professor, Stanford University Medical Center
Jay Greenspan, MD Department Chair, Newborn Pediatrics, Thomas Jefferson University Hospital
Pasquale Casale, MD Pediatric urology, Children’s Hospital of Philadelphia (CHOP)
30
CLS, Inc. Pre-money valuation• Valuation of $1.5M
• Sale of $25K blocks
• Liabilities of $320K
• $1M investment gains 40% of CLS
• Management has made significant cash and human capital investment of $750K in getting the product poised for the final push to market
31
Use of proceedsProject manager, 18 months $135K
Re-design $180K
Safety Testing $ 25K
Clinical Trial $ 25K
Regulatory Consulting $ 45K
Legal and Accounting $ 30K
Product Launch: device manufacturing $500K
Marketing/business development $ 60K
TOTAL: $1,000,000
32
The End Game: Pathway to the
marketplace A. B.
Clinical trial concurrent with product re-design
Submission of 510(k)
FDA clearance
EXIT: Sale of CLS
Clinical trial concurrent with product re-design
Submission of 510(k)
FDA clearance
Manufacturing of SB for sales to US luminary hospitals
EXIT: Sale of CLS
33
The Endgame: Early Exit…Sell to whom?
34
Why invest in Columbia Life Systems, Inc.?
Business• Novel Intellectual property• Cutting edge technology: smart technology does not
exist in the marketplace today - NO COMPETITION
• Significant market pull from doctors and clinicians• Better medicine: may improve lung health in long run
which reduces healthcare costs• Reduces hospital expenditures: pilot studies reveal
the weaning of patients off oxygen sooner, saving hospitals hard dollars in NICU costs
• Early exit strategy: quick return on investment• Below market valuation• Excellent projected ROI based on expected valuation
35
Why invest in Columbia Life Systems, Inc.?
Medicine• Leads respiratory care management into the 21st century
• Significant therapeutic receptivity from doctors and clinicians
• May increase respiratory health for patients in NICU/ICU: optimizes manner to dispense oxygen based on patient physiological demand
• Better medicine: may improve lung health in long run
• Pilot studies show weaning patients off of oxygen sooner; may expedite release from hospital/NICU earlier
36
Columbia Life Systems SmartBlender™
Making babies healthier
one breath at a time.
37
Columbia Life Systems:
Entering a new frontier inrespiratory care management
respir Thank you
38